Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy

Neuron

Volumn 35, Issue 5, 2002, Pages 843-854

  Katsuno, Masahisa ^a   Adachi, Hiroaki ^a   Kume, Akito ^a   Li, Mei ^a   Nakagomi, Yuji ^b   Niwa, Hisayoshi ^a   Sang, Chen ^a   Kobayashi, Yasushi ^a   Doyu, Manabu ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; MUTANT PROTEIN; POLYGLUTAMINE; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CASTRATION; CELL NUCLEUS TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KENNEDY DISEASE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SEX DIFFERENCE; STAINING; TRANSGENIC MOUSE; WESTERN BLOTTING;

EID: 18644379256     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(02)00834-6     Document Type: Article

References (62)

1. Abel A., Walcott J., Woods J., Duda J., Merry D.E. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum. Mol. Genet. 10:2001;107-116.
2. Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Do J., Sang C., Kobayashi Y., Doyu M., Sobue G. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum. Mol. Genet. 10:2001;1039-1048.
3. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R.et al. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8:2001;479-491.
4. Bingham P.M., Scott M.O., Wang S., McPhaul M.J., Wilson E.M., Garbern J.Y., Merry D.E., Fischbeck K.H. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. Nat. Genet. 9:1995;191-196.
5. Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22:1994;3181-3186.
6. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19:1998;148-154.
7. Cummings C.J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A., Orr H.T., Beaudet A.L., Zoghbi H.Y. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 24:1999;879-892.
8. Cummings C.J., Sun Y., Opal P., Antalffy B., Mestril R., Orr H.T., Dillmann W.H., Zoghbi H.Y. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet. 10:2001;1511-1518.
9. Danek A., Witt T.N., Mann K., Schweikert H.U., Romalo G., La Spada A.R., Fischbeck K.H. Decrease in androgen binding and effect of androgen treatment in a case of X-linked bulbospinal neuronopathy. Clin. Investig. 72:1994;892-897.
10. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., Folstein S., Ross C., Franz M., Abbott M.et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4:1993;387-392.
11. Doyu M., Sobue G., Mukai E., Kachi T., Yasuda T., Mitsuma T., Takahashi A. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann. Neurol. 32:1992;707-710.
12. Goldenberg J.N., Bradley W.G. Testosterone therapy and the pathogenesis of Kennedy's disease (X-linked bulbospinal muscular atrophy). J. Neurol. Sci. 135:1996;158-161.
13. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease. relationship to neuropathology J. Neurosci. 19:1999;2522-2534.
14. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules. implications for Huntington's disease therapy Proc. Natl. Acad. Sci. USA. 97:2000;6739-6744.
15. Igarashi S., Tanno Y., Onodera O., Yamazaki M., Sato S., Ishikawa A., Miyatani N., Nagashima M., Ishikawa Y., Sahashi K.et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology. 42:1992;2300-2302.
16. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A.et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18:1998;111-117.
17. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8:2002;143-149.
18. Kazemi-Esfarjani P., Trifiro M.A., Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor. possible pathogenetic relevance for the (CAG)n-expanded neuronopathies Hum. Mol. Genet. 4:1995;523-527.
19. Kemppainen J.A., Lane M.V., Sar M., Wilson E.M. Androgen receptor phosphorylation, turnover, nuclear transport and transcriptional activation. J. Biol. Chem. 267:1992;968-974.
20. Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 18:1968;671-680.
21. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation. role in polyglutamine-induced disease in SCA1 transgenic mice Cell. 95:1998;41-53.
22. Kobayashi Y., Miwa S., Merry D.E., Kume A., Mei L., Doyu M., Sobue G. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. Biochem. Biophys. Res. Commun. 252:1998;145-150.
23. Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K., Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275:2000;8772-8778.
24. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 352:1991;77-79.
25. La Spada A.R., Roling D.B., Harding A.E., Warner C.L., Spiegel R., Hausmanowa-Petrusewicz I., Yee W.C., Fischbeck K.H. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 2:1992;301-304.
26. La Spada A.R., Peterson K.R., Meadows S.A., McClain M.E., Jeng G., Chmelar R.S., Haugen H.A., Chen K., Singer M.J., Moore D.et al. Androgen receptor YAC transgenic mice carrying CAG 45 alleles show trinucleotide repeat instability. Hum. Mol. Genet. 7:1998;959-967.
27. Li M., Miwa S., Kobayashi Y., Merry D.E., Yamamoto M., Tanaka F., Doyu M., Hashizume Y., Fischbeck K.H., Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. 44:1998;249-254. a.
28. Li M., Nakagomi Y., Kobayashi Y., Merry D.E., Tanaka F., Doyu M., Mitsuma T., Hashizume Y., Fischbeck K.H., Sobue G. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am. J. Pathol. 153:1998;695-701. b.
29. MacLean H.E., Warne G.L., Zajac J.D. Defects of androgen receptor function. from sex reversal to motor neurone disease Mol. Cell. Endocrinol. 112:1995;133-141.
30. Mariotti C., Castellotti B., Pareyson D., Testa D., Eoli M., Antozzi C., Silani V., Marconi R., Tezzon F., Siciliano G.et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females. a clinical and molecular study of 30 families Neuromuscul. Disord. 10:2000;391-397.
31. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., Merry D., Chai Y., Paulson H., Sobue G., Fischbeck K.H. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9:2000;2197-2202.
32. McPhaul M.J., Marcelli M., Zoppi S., Griffin J.E., Wilson J.D. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. J. Clin. Endocrinol. Metab. 76:1993;17-23.
33. Mende-Mueller L.M., Toneff T., Hwang S.R., Chesselet M.F., Hook V.Y. Tissue-specific proteolysis of Huntingtin (htt) in human brain. evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum J. Neurosci. 21:2001;1830-1837.
34. Merry D.E., McCampbell A., Taye A.A., Winston R.L., Fischbeck K.H. Toward a mouse model for spinal and bulbar muscular atrophy. effect of neuronal expression of androgen receptor in transgenic mice Am. J. Hum. Genet. Suppl. 59:1996;A271.
35. Mhatre A.N., Trifiro M.A., Kaufman M., Kazemi-Esfarjani P., Figlewicz D., Rouleau G., Pinsky L. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 5:1993;184-188.
36. Morrison J.P., McManamny P., O'Bryan K.M., Cimdins K.L., Kola I., Cheema S., deKretser D.M. A mouse model of spinal bulbar muscular atrophy (SBMA). Am. J. Hum. Genet. Suppl. 67:2000;A51.
37. Nakajima H., Kimura F., Nakagawa T., Furutama D., Shinoda K., Shimizu A., Ohsawa N. Transcriptional activation by the androgen receptor in X-linked spinal and bulbar muscular atrophy. J. Neurol. Sci. 142:1996;12-16.
38. Neuschmid-Kaspar F., Gast A., Peterziel H., Schneikert J., Muigg A., Ransmayr G., Klocker H., Bartsch G., Cato A.C. CAG-repeat expansion in androgen receptor in Kennedy's disease is not a loss of function mutation. Mol. Cell. Endocrinol. 117:1996;149-156.
39. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108:1991;193-199.
40. Nucifora F.C. Jr., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L.et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
41. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E.et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:1999;263-267.
42. Orr H.T., Chung M.Y., Banfi S., Kwiatkowski T.J. Jr., Servadio A., Beaudet A.L., McCall A.E., Duvick L.A., Ranum L.P., Zoghbi H.Y. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 4:1993;221-226.
43. Paulson H.L. Toward an understanding of polyglutamine neurodegeneration. Brain Pathol. 10:2000;293-299.
44. Peters M.F., Nucifora F.C. Jr., Kushi J., Seaman H.C., Cooper J.K., Herring W.J., Dawson V.L., Dawson T.M., Ross C.A. Nuclear targeting of mutant Huntingtin increases toxicity. Mol. Cell. Neurosci. 14:1999;121-128.
45. Rubinsztein D.C. Lessons from animal models of Huntington's disease. Trends Genet. 18:2002;202-209.
46. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66.
47. Simeoni S., Mancini M.A., Stenoien D.L., Marcelli M., Weigel N.L., Zanisi M., Martini L., Poletti A. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum. Mol. Genet. 9:2000;133-144.
48. Sobue G., Hashizume Y., Mukai E., Hirayama M., Mitsuma T., Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain. 112:1989;209-232.
49. Sobue G., Doyu M., Kachi T., Yasuda T., Mukai E., Kumagai T., Mitsuma T. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J. Neurol. Sci. 117:1993;74-78.
50. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA. 97:2000;6763-6768.
51. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M.et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 413:2001;739-743.
52. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N., Marcelli M., Weigel N.L., Mancini M.A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 8:1999;731-741.
53. Syms A.J., Norris J.S., Panko W.B., Smith R.G. Mechanism of androgen-receptor augmentation. analysis of receptor synthesis and degradation by the density-shift technique J. Biol. Chem. 260:1985;455-461.
54. Tanaka F., Reeves M.F., Ito Y., Matsumoto M., Li M., Miwa S., Inukai A., Yamamoto M., Doyu M., Yoshida M.et al. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor-gene expression level. Am. J. Hum. Genet. 65:1999;966-973.
55. Terao S., Sobue G., Hashizume Y., Li M., Inagaki T., Mitsuma T. Age-related changes in human spinal ventral horn cells with special reference to the loss of small neurons in the intermediate zone. a quantitative analysis Acta Neuropathol. (Berl.). 92:1996;109-114.
56. Trottier Y., Lutz Y., Stevanin G., Imbert G., Devys D., Cancel G., Saudou F., Weber C., David G., Tora L.et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 378:1995;403-406.
57. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23:1999;425-428.
58. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M.et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273:1998;9158-9167.
59. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:2000;57-66.
60. Zhou Z.X., Wong C.I., Sar M., Wilson E.M. The androgen receptor. an overview Recent Prog. Horm. Res. 49:1994;249-274.
61. Zhou Z.X., Lane M.V., Kemppainen J.A., French F.S., Wilson E.M. Specificity of ligand-dependent androgen receptor stabilization. receptor domain interactions influence ligand dissociation and receptor stability Mol. Endocrinol. 9:1995;208-218.
62. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23:2000;217-247.